Evidence map›Paper›PMID 41925882›Full record

ArticleMedical microbiology and immunology2026

The small GTPase Rab5 inhibits actin polymerization mediated by the Legionella pneumophila effector VipA.

Joana Saraiva, Joana N Bugalhão, Teresa Carvalho, Zach Hensel, Alvaro Crevenna, L Jaime Mota, Irina S Franco

Abstract read
In one paragraph

Article in Medical microbiology and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joana Saraiva *UCIBIO-Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, NOVA University Lisbon, Caparica, Portugal.
Joana N Bugalhão *UCIBIO-Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, NOVA University Lisbon, Caparica, Portugal.
Teresa CarvalhoUCIBIO-Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, NOVA University Lisbon, Caparica, Portugal.
Zach HenselInstituto de Tecnologia Química e Biológica, NOVA University Lisbon, Oeiras, Portugal.
Alvaro CrevennaInstituto de Tecnologia Química e Biológica, NOVA University Lisbon, Oeiras, Portugal.
L Jaime MotaUCIBIO-Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, NOVA University Lisbon, Caparica, Portugal.
Irina S FrancoUCIBIO-Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, NOVA University Lisbon, Caparica, Portugal. irinafranco@fct.unl.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Legionella pneumophila is a facultative intracellular bacterium that causes Legionnaires’ disease, one of the most severe manifestations of atypical pneumonia. The capacity of L. pneumophila to cause disease relates with its ability to survive and multiply inside a membrane-bound compartment, the Legionella-containing vacuole (LCV). The remodeling of the LCV into a replication-competent compartment requires the Icm/Dot type 4 secretion system, that translocates over 300 bacterial effector proteins into host cells. Their action is concerted spatially and timely in order to modulate a multitude of host cell targets and thus ensure LCV segregation from the phagolysosomal pathway. The L. pneumophila effector VipA associates with early endosomes and promotes the nucleation of new actin filaments in vitro. Additionally, ectopically produced VipA impairs vesicle trafficking in Saccharomyces cerevisiae. However, the mechanisms underlying its association with the endocytic pathway have remained elusive. In this work, we sought the molecular interacting partners of VipA in early endosomes and explored the effects of this association. We found that VipA interacts directly with two key components of these organelles, the membrane lipid phosphoinositide 3-phosphate (PI3P) and the small GTPase Rab5. Binding to Rab5 requires the NH2-terminal region of VipA but not the COOH-terminal/actin-binding region. Furthermore, binding to Rab5 inhibits VipA-mediated actin polymerization by preventing de novo actin filament formation. These findings offer new insights into the mode of action of VipA and underscore the intricate network of interactions between L. pneumophila effectors and their host cell targets, namely in the endocytic pathway.

Indexed as

ActinsBacterial ProteinsHost-Pathogen InteractionsLegionella pneumophilarab5 GTP-Binding ProteinsEndosomesHumansPhosphatidylinositol PhosphatesPolymerizationProtein BindingProtein Interaction MappingVacuolesActinsBacterial Proteinsphosphatidylinositol 3-phosphatePhosphatidylinositol Phosphatesrab5 GTP-Binding ProteinsActin polymerizationEndocytic pathwayLegionella pneumophilaPI3PRab5VipA

Identifiers

PMID41925882
PMCPMC13046614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.